Other promising MoAbs in MM treatment are elotuzumab, an anti-SLAMF7 (or CD319), approved in combination with lenalidomide and dexamethasone in relapsed/refractory MM patients [153], and belantamab mafodotin, an anti-B cell maturating antigen (BCMA) MoAb conjugated with a monomethyl auristatin F, approved as monotherapy in MM patients with disease progression who are refractory to proteasome inhibitors, IMiDs, and anti-CD38 MoAbs [154]. The gene discussed is CD38; the disease is Miyoshi myopathy.